|
Monday, 08/02/2010
|
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
Daniel Sargent, Mayo Clinic; Sumithra Mandrekar, Mayo Clinic
10:35 AM
|
Statistics in Biopharmaceutical Research: Application of Biomarkers in Drug Development
Aloka Chakravarty, FDA; Mark Rothmann, FDA; Rajeshwari Sridhara , FDA
2:05 PM
|
Evaluating Correlation and Some Misuses for Biomarker Qualification Within a Causal Correlation Framework
Yue Wang, Merck & Co., Inc.; Robin Mogg, Merck & Co., Inc.; Peter H. Hu, Merck & Co., Inc.; Jared Lunceford, Merck & Co., Inc.; Peggy Wong, Merck Research Laboratories
2:05 PM
|
Using Logistic Model with Measurement Errors in Covariates to Assess Baseline Biomarkers Association with Treatment Response
Dion Chen, Centocor R&D, Inc.; Jiandong Lu, Johnson & Johnson
2:35 PM
|
Design and Analysis of Discrete-Time Survival Studies with Pooled Biomarker Assessment
Paramita Saha, National Institute of Environmental Health Sciences; Clarice R. Weinberg, National Institute of Environmental Health Sciences
2:45 PM
|
Issues on Threshold Selection in Predictive Biomarker Analysis
Li-an Xu, Bristol-Myers Squibb
3:20 PM
|
|
Tuesday, 08/03/2010
|
Developing Targeted Protein Measurement for Label-Free Multiple Reaction Monitoring
Dean Billheimer, The University of Arizona
8:55 AM
|
Mixed-Effect Models for High-Throughput Mass Spectrometry-Based Proteomic Profiling Experiments
Timothy Clough, Purdue University; Ching-Yun (Veavi) Chang, Purdue University; Olga Vitek, Purdue University
9:15 AM
|
I-SPY2: Identifying Biomarker Signatures for Therapeutic Agents in Neoadjuvant Breast Cancer
Donald Arthur Berry, MD Anderson Cancer Center; Kyle Wathen, MD Anderson Cancer Center; Nebiyou Bekele, MD Anderson Cancer Center; Laura Esserman, University of California, San Francisco
11:35 AM
|
Robust ROC Analysis Using Auxiliary Variables in the Presence of Missing Biomarker Values
Xiaoxi Zhang, Pfizer Inc.; Qi Long, Emory University
3:05 PM
|
Assessing the Improved Discriminatory Power of a New Biomarker in Prognostic Models
Mei Liu, MD Anderson Cancer Center; Carol J. Etzel, MD Anderson Cancer Center; Asha Kapadia, The University of Texas School of Public Health
3:05 PM
|
|
Wednesday, 08/04/2010
|
Accuracy of Biomarker Testing and Its Impact on Targeted Therapy Validation
Meijuan Li, FDA; Estelle Russek-Cohen, FDA; Rong Tang, FDA
9:15 AM
|
A Nonparametric Bayesian Approach to Biomarker Discovery
Peter Mueller, MD Anderson Cancer Center; Alejandro Jara, Pontificia Universidad Católica de Chile
11:15 AM
|
Methodological Challenges in Linking NHANES Biomarker Data with Ambient Air Data and Surrogate Measures of Traffic-Related Air Pollution
Sorina Eftim, University of Maryland; Amir Sapkota, University of Maryland; Jennifer Parker, National Center for Health Statistics
2:35 PM
|
Diffusion Tensor Imaging (DTI) as a Potential Biomarker of Autism
Moo K. Chung, University of Wisconsin
3:05 PM
|
|